Craig Lammert1, Brian D Juran1, Erik Schlicht1, Xiao Xie2, Elizabeth J Atkinson2, Mariza de Andrade2, Konstantinos N Lazaridis3. 1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota. 2. Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota. 3. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: lazaridis.konstantinos@mayo.edu.
Abstract
BACKGROUND & AIMS: Coffee consumption has been associated with decreased risk of liver disease and related outcomes. However, coffee drinking has not been investigated among patients with cholestatic autoimmune liver diseases, primary biliary cirrhosis (PBC), or primary sclerosing cholangitis (PSC). We investigated the relationship between coffee consumption and risk of PBC and PSC in a large North American cohort. METHODS: Lifetime coffee drinking habits were determined from responses to questionnaires from 606 patients with PBC, 480 with PSC, and 564 healthy volunteers (controls). Patients (those with PBC or PSC) were compared with controls by using the Wilcoxon rank sum test for continuous variables and c(2) method for discrete variables. Logistic regression was used to analyze the estimate of the effects of different coffee parameters (time, frequency, and type of coffee consumption) after adjusting for age, sex, smoking status, and education level. RESULTS: Patients with PBC and controls did not differ in coffee parameters. However, 24% of patients with PSC had never drunk coffee compared with 16% of controls (P < .05), and only 67% were current drinkers compared with 77% of controls (P < .05). Patients with PSC also consumed fewer lifetime cups per month (45 vs 47 for controls, P < .05) and spent a smaller percentage of their lifetime drinking coffee (46.6% vs 66.7% for controls, P < .05). These differences remained significant in a multivariate model. Among PSC patients with concurrent ulcerative colitis, coffee protected against proctocolectomy (hazard ratio, 0.34; P < .001). CONCLUSIONS: Coffee consumption is lower among patients with PSC, but not PBC, compared with controls.
BACKGROUND & AIMS: Coffee consumption has been associated with decreased risk of liver disease and related outcomes. However, coffee drinking has not been investigated among patients with cholestatic autoimmune liver diseases, primary biliary cirrhosis (PBC), or primary sclerosing cholangitis (PSC). We investigated the relationship between coffee consumption and risk of PBC and PSC in a large North American cohort. METHODS: Lifetime coffee drinking habits were determined from responses to questionnaires from 606 patients with PBC, 480 with PSC, and 564 healthy volunteers (controls). Patients (those with PBC or PSC) were compared with controls by using the Wilcoxon rank sum test for continuous variables and c(2) method for discrete variables. Logistic regression was used to analyze the estimate of the effects of different coffee parameters (time, frequency, and type of coffee consumption) after adjusting for age, sex, smoking status, and education level. RESULTS:Patients with PBC and controls did not differ in coffee parameters. However, 24% of patients with PSC had never drunk coffee compared with 16% of controls (P < .05), and only 67% were current drinkers compared with 77% of controls (P < .05). Patients with PSC also consumed fewer lifetime cups per month (45 vs 47 for controls, P < .05) and spent a smaller percentage of their lifetime drinking coffee (46.6% vs 66.7% for controls, P < .05). These differences remained significant in a multivariate model. Among PSCpatients with concurrent ulcerative colitis, coffee protected against proctocolectomy (hazard ratio, 0.34; P < .001). CONCLUSIONS: Coffee consumption is lower among patients with PSC, but not PBC, compared with controls.
Authors: Marlies Noordzij; Cuno S P M Uiterwaal; Lidia R Arends; Frans J Kok; Diederick E Grobbee; Johanna M Geleijnse Journal: J Hypertens Date: 2005-05 Impact factor: 4.844
Authors: J M Farrant; K M Hayllar; M L Wilkinson; J Karani; B C Portmann; D Westaby; R Williams Journal: Gastroenterology Date: 1991-06 Impact factor: 22.682
Authors: C C Blackwell; K Jónsdóttir; M Hanson; W T Todd; A K Chaudhuri; B Mathew; R P Brettle; D M Weir Journal: Lancet Date: 1986-08-02 Impact factor: 79.321
Authors: E V Loftus; W J Sandborn; W J Tremaine; D W Mahoney; A R Zinsmeister; K P Offord; L J Melton Journal: Gastroenterology Date: 1996-05 Impact factor: 22.682
Authors: U Broomé; R Olsson; L Lööf; G Bodemar; R Hultcrantz; A Danielsson; H Prytz; H Sandberg-Gertzén; S Wallerstedt; G Lindberg Journal: Gut Date: 1996-04 Impact factor: 23.059
Authors: J E Eaton; B D Juran; E J Atkinson; E M Schlicht; X Xie; M de Andrade; C S Lammert; V A Luketic; J A Odin; A A Koteish; K V Kowdley; K B Chopra; G M Hirschfield; N P Chalasani; K N Lazaridis Journal: Aliment Pharmacol Ther Date: 2015-03-17 Impact factor: 8.171
Authors: Douglas I Walker; Brian D Juran; Angela C Cheung; Erik M Schlicht; Yongliang Liang; Megan Niedzwiecki; Nicholas F LaRusso; Gregory J Gores; Dean P Jones; Gary W Miller; Konstantinos N Lazaridis Journal: Hepatol Commun Date: 2021-11-26
Authors: Juan-Manuel Anaya; Carolina Ramirez-Santana; Maria A Alzate; Nicolas Molano-Gonzalez; Adriana Rojas-Villarraga Journal: Front Immunol Date: 2016-04-26 Impact factor: 7.561
Authors: Megan Comerford; Rachel Fogel; James Robert Bailey; Prianka Chilukuri; Naga Chalasani; Craig Steven Lammert Journal: J Med Internet Res Date: 2018-01-18 Impact factor: 5.428